Toll Free: 1-888-928-9744

Sareum Holdings Plc - Product Pipeline Review - 2016

Published: Dec, 2016 | Pages: 37 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Sareum Holdings Plc - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Sareum Holdings Plc - Product Pipeline Review - 2016', provides an overview of the Sareum Holdings Plc's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Sareum Holdings Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Sareum Holdings Plc
- The report provides overview of Sareum Holdings Plc including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Sareum Holdings Plc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Sareum Holdings Plc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Sareum Holdings Plc's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Sareum Holdings Plc
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sareum Holdings Plc's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Sareum Holdings Plc Snapshot 6 Sareum Holdings Plc Overview 6 Key Facts 6 Sareum Holdings Plc - Research and Development Overview 7 Key Therapeutic Areas 7 Sareum Holdings Plc - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Sareum Holdings Plc - Pipeline Products Glance 14 Sareum Holdings Plc - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 Sareum Holdings Plc - Drug Profiles 16 CCT-244747 - Drug Profile 16 Product Description 16 Mechanism Of Action 16 R&D Progress 16 SAR-020106 - Drug Profile 18 Product Description 18 Mechanism Of Action 18 R&D Progress 18 SAR-20347 - Drug Profile 20 Product Description 20 Mechanism Of Action 20 R&D Progress 20 SAR-3 - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 SAR-4 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 SART-1 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 SART-29 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 SART-33 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Sareum Holdings Plc - Pipeline Analysis 28 Sareum Holdings Plc - Pipeline Products by Target 28 Sareum Holdings Plc - Pipeline Products by Route of Administration 29 Sareum Holdings Plc - Pipeline Products by Molecule Type 30 Sareum Holdings Plc - Pipeline Products by Mechanism of Action 31 Sareum Holdings Plc - Dormant Projects 32 Sareum Holdings Plc - Company Statement 33 Sareum Holdings Plc - Locations And Subsidiaries 35 Head Office 35 Other Locations & Subsidiaries 35 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 36 Disclaimer 37
List of Tables
Sareum Holdings Plc, Key Facts 6 Sareum Holdings Plc - Pipeline by Indication, 2016 8 Sareum Holdings Plc - Pipeline by Stage of Development, 2016 10 Sareum Holdings Plc - Monotherapy Products in Pipeline, 2016 11 Sareum Holdings Plc - Out-Licensed Products in Pipeline, 2016 12 Sareum Holdings Plc - Out-Licensed Products/ Combination Treatment Modalities, 2016 13 Sareum Holdings Plc - Preclinical, 2016 14 Sareum Holdings Plc - Discovery, 2016 15 Sareum Holdings Plc - Pipeline by Target, 2016 28 Sareum Holdings Plc - Pipeline by Route of Administration, 2016 29 Sareum Holdings Plc - Pipeline by Molecule Type, 2016 30 Sareum Holdings Plc - Pipeline Products by Mechanism of Action, 2016 31 Sareum Holdings Plc - Dormant Developmental Projects,2016 32 Sareum Holdings Plc, Subsidiaries 35



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify